Aim To investigate maternal, perinatal, and neonatal outcomes of pregnancies in women with type 1 diabetes in the University Maternity Hospital Limerick, Ireland.

Methods This retrospective descriptive study was conducted from charts identified from the diabetes in pregnancy register from 1st July 2007 to 1st July 2017 at University Maternity Hospital Limerick.

Results 17 women were identified from the register with juvenile onset (<18 years) type 1 diabetes mellitus during the 10 year study period who gave birth to 23 live infants. Maternal diabetes related medical conditions included; diabetic retinopathy (29%), hypertension (11.8%), recurrent urinary tract infections (11.8%), diabetic nephropathy (11.8%), poor glycaemia awareness (11.8%), diabetic neuropathy (5.9%) and cataracts (5.9%). 11.7% women had a past history of illicit drug use. 8.7% women were smoking at the time of booking. Antenatal obstetric complications included polyhydramnios (17.4%), intrauterine growth restriction (17.4%), pre-eclampsia (8.7%), maternal hypertensive seizure (4.3%) and pregnancy induced hypertension (4.3%). 39.1% infants were born to primiparous women. 87% infants were bottle-fed. 73.9% births were unplanned pregnancies. Of n=5 infants born via vaginal delivery there were no cases of shoulder dystocia. 60.9% neonates were male. The mean gestation was 37.2 weeks (range 33.3 to 39.4). The mean birth weight was 3.57 kg (range 2.01 to 5.54). The median APGAR at 1 minute was 9 (range 33.3 to 39.4). The mean birth weight was 3.57 kg (range 2.01 to 5.54). The median APGAR at 5 minutes was 10 (range 33.3 to 39.4). The mean APGAR at 5 minutes was 10 (range 4–10). 17.4% neonates required free flow O2 at birth and 8.7% required bag-mask ventilation. 95.7% neonates were admitted to the neonatal unit. Of the n=23 infants studied medical issues included; hypoglycaemia (60.9%), jaundice requiring phototherapy (43.5%), transient tachypnoea of the newborn (39.1%), prematurity (30.4%), macrosomia (17.4%), low birth weight (13%), poor feeding (13%), polycythaemia (8.7%), trismus (4.3%), respiratory distress syndrome (4.3%) and hyponatraemia (4.3%).

Conclusion Neonates born to mothers with juvenile onset T1DM should be considered a high risk group and clinicians should have a low threshold for admission to the neonatal unit.

P294 CUSHING SYNDROME AND ADRENAL INSUFFICIENCY INDUCED BY HIGH DOSE PROLONGED INTRANASAL BETAMETHASONE

1Claire Reynolds*, 1Pankaj Agrawal, 1Atsiling McCann, 2Triona O’Sullivan, 3Muirneann Ni Chronin, 1Stephen MP O’Riordan. 1Department of Paediatric and Endocrinology, Cork University Hospital, Cork, Ireland; 2Pharmacy Department, Cork University Hospital, Cork, Ireland; 3Department of Paediatric and Respiratory Medicine, Cork University Hospital, Cork, Ireland

10.1136/archdischild-2019-epa.644

Iatrogenic Cushing syndrome and secondary adrenal insufficiency due to intranasal steroids is rare in children. A 7 year old boy was referred to the paediatric endocrine clinic with suspected Cushing syndrome. He presented with excessive weight gain, marked striae and hypertension. His GP had performed a morning cortisol <28mol/L (171–800mol/L). He had a background history of obstructive sleep apnoea for which he had been prescribed Betnesol 0.1% (Betamethasone sodium phosphate 1 mg/ml) nasal drops and Montelukast 4 mg daily. Physical examination revealed hypertrichosis on his back, buffalo-humped neck, and purple striae on his legs and inner thighs. He was Tanner stage 1, normal genitalia. Auxology: weight 46.1 kg (>99.6th centile); height 124.6 cm (50th, 75th centile), body mass index (BMI) 30 kg/m2 (>99.6th centile) and blood pressure was 124/72 mmHg (>99th centile). The drug history was reviewed in detail by our Paediatric Pharmacist and revealed that over the past 20 months, he had been using betamethasone nasal drops continuously, prescribed at a dose of 2 drops, twice daily, into each nostril. A total of 38 repeat prescriptions had been dispensed and he had been taking double the prescribed amount per month. The duration of use (20 months) also far exceeded the recommended indication (4–6weeks max). Laboratory investigations: blood glucose 4.7 mmol/L, early morning cortisol <28 mmol/L (171–800mmol/L) and ACTH <0.2 undetectable (1.1–13.2mmol/L). Renin and aldosterone, anti-21 hydroxylase antibodies, thyroid function tests, IGF-1, coeliac screen, and renal/liver/bone were all normal. A short synacthen test (250micrograms) confirmed HPA axis suppression for our patient (cortisol concentrations: <28nmol/L at time; 0 mins, 30 mins and 60 mins). This is gold standard diagnostic test when adrenal suppression is suspected. He was immediately commenced on replacement hydrocortisone therapy at a dose of 8–10 mg/m²/day. He was also educated on emergency hydrocortisone administration and stress dosing. He will continue on hydrocortisone until his HPA axis recovers. Betamethasone is a potent steroid 25–30 times more potent than hydrocortisone

Conclusion We describe a case of iatrogenic Cushing syndrome and adrenal insufficiency secondary to administration of long-term high-dose betamethasone nasal drops. Very few cases to date have been reported in the literature in children. Cushing syndrome caused by intranasal steroids is a rare event and more commonly occurs after oral or topical steroid use. Our patient was taking double the recommended dose for more than 20 months. Paediatricians must be aware of the complications of nasal steroid administration and long-term use should be avoided.

P295 CHARACTERISTICS OF A POPULATION OF 311 PATIENTS OF BOTH SEXES WITH EARLY ONSET PUBERTAL SIGNS. DESCRIPTIVE STUDY

1Paula Sol Ventura Wichner, 1Xavier Herrero, 1Maria Laura Llorca, 1Agustina Magistri, 1Zelmira Bosch, 1Marisa Torres Lacruz, 2Georges Denis Akel Perez*. 1Hospital de Nens, Barcelona, Spain; 2Paediatric Unit of Fundación Hospital de Nens de Barcelona, Barcelona, Spain

10.1136/archdischild-2019-epa.645

Objective To assess anthropometric, biochemical and imaging studies (bone age, pelvic ultrasound and MRJ) in patients who consulted the Endocrinology Department of the Hospital de Nens de Barcelona, referred by pediatricians to discard precocious puberty.

Methodology Retrospective descriptive study based on review of medical records, with first consultation between 2010 and 2018. Search from keyword in the diagnosis: puberty. The subjects were separated in 6 groups: involved precocious breast development, early non-progressive breast development, central precocious puberty (PPC), peripheral precocious...
puberty (PPP), advanced puberty and rapidly progressive puberty. Exclusion criteria: not going to follow-up visits. Statistical analysis by SPSS 23.

**Results** A total of 311 subjects (14 men, 297 women) who were referred by their pediatricians, attended the first visit to the endocrinology department with an average age of 7.8 years (95% CI: 7.7–8). The distribution of subjects was: involuted precocious breast development (n = 25), non-progressive precocious breast development (n = 19), PPC (n = 156), PPP (n = 3), advanced puberty (n = 88) and rapidly progressive puberty (n = 20). Male subjects who were diagnosed of precocious puberty had at first visit a mean age of 8.7 years (95% CI: 7.8–9.5), and women had a mean age of 7.7 years (95% CI: 7.5–8). There are significant differences regarding bone age at diagnosis (more advanced in central precocious puberty and rapidly progressive puberty). There is a statistically significant association between precocious puberty and the fact of being adopted (X2: 11.2; p: 0.046). The LH at 3 hours of the GnRH test was significantly higher in the PPC group (mean value of LH 14U/L, IC95%: 11.5–16.6) compared to the others. Patients were identified who did not meet the classic criteria of the diagnosis of PPC in the Procrin test, however they present clinical characteristics in the follow-up that led to the diagnosis. MRI: significant association between having MRI findings and presenting PPC (X2: 38.262; p: 0.000), however incidental findings where found in MRI of patients with advanced puberty. A total of 69% of patients with PPC and 17.6% patients with advanced puberty received MRI of patients with advanced puberty. A total of 69% of patients with PPC and 17.6% patients with advanced puberty (including here the rapidly progressive forms) received treatment.

**Conclusions** We present the data of a population of children of both sexes with clinical manifestations suggestive of precocious/advanced puberty evaluated and followed between the years 2010 and 2018. The results coincide with those described in previous studies.

---

**P297**

**CONSTANT UNCERTAINTY: MOTHERS’ EXPERIENCES OF CARING FOR CHILDREN RECEIVING GROWTH HORMONE TREATMENT (GHT)**

1\textsuperscript{1}Rasha Alsaihi**, 1Imelda Coyne. 1King Abdulaziz University, College of Nursing, Jeddah, Saudi Arabia; 2Trinity College Dublin, School of Nursing and Midwifery, Dublin, Ireland

Uncertainty has been noted as a significant feature of parental experiences of childhood chronic illnesses needing medical treatments in general and growth hormone treatment (GHT) in particular. However, there is insufficient research exploring the extent of which uncertainty features in the experiences of parents caring for children receiving GHT or the dimensions, which their uncertainty may take. Drawn from 16 in depth interviews and eight diaries from 16 mothers from the Republic of Ireland who had children with a growth disorder requiring daily administration of GHT, this paper highlights their experiences of uncertainty when it comes to dealing with GHT. It was concluded that the dimensions of uncertainty experienced by the mothers were: diagnostic, treatment, future and social stigma uncertainty. It also demonstrates the significant challenges of coping with these uncertainties. By recognising the dimensions of uncertainty faced by mothers caring for children receiving GHT, health care professionals can anticipate these uncertainties and help minimise some of the stress and anxiety associated with them.